Fig. 1From: Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort studyConsort diagram illustrating the treatment flow of patientsBack to article page